SG11201606839SA - Substituted cyclopentanes, tetrahydrofuranes and pyrrolidines as orexin receptor antagonists - Google Patents
Substituted cyclopentanes, tetrahydrofuranes and pyrrolidines as orexin receptor antagonistsInfo
- Publication number
- SG11201606839SA SG11201606839SA SG11201606839SA SG11201606839SA SG11201606839SA SG 11201606839S A SG11201606839S A SG 11201606839SA SG 11201606839S A SG11201606839S A SG 11201606839SA SG 11201606839S A SG11201606839S A SG 11201606839SA SG 11201606839S A SG11201606839S A SG 11201606839SA
- Authority
- SG
- Singapore
- Prior art keywords
- tetrahydrofuranes
- pyrrolidines
- receptor antagonists
- orexin receptor
- substituted cyclopentanes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14156010 | 2014-02-20 | ||
| PCT/GB2015/050482 WO2015124934A1 (en) | 2014-02-20 | 2015-02-19 | Subsituted cyclopentanes, tetrahydrofuranes and pyrrolidines as orexin receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201606839SA true SG11201606839SA (en) | 2016-09-29 |
Family
ID=50115775
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201606839SA SG11201606839SA (en) | 2014-02-20 | 2015-02-19 | Substituted cyclopentanes, tetrahydrofuranes and pyrrolidines as orexin receptor antagonists |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US9790220B2 (es) |
| EP (1) | EP3107907A1 (es) |
| JP (1) | JP6466465B2 (es) |
| KR (1) | KR20160124188A (es) |
| CN (1) | CN106164064B (es) |
| AU (1) | AU2015220553B2 (es) |
| CA (1) | CA2940047A1 (es) |
| CL (1) | CL2016002085A1 (es) |
| CR (1) | CR20160373A (es) |
| EA (1) | EA031982B1 (es) |
| EC (1) | ECSP16074482A (es) |
| GE (1) | GEP20186909B (es) |
| IL (1) | IL247195A0 (es) |
| MA (1) | MA39229A1 (es) |
| MX (1) | MX2016010745A (es) |
| PE (1) | PE20161374A1 (es) |
| PH (1) | PH12016501625A1 (es) |
| SG (1) | SG11201606839SA (es) |
| WO (1) | WO2015124934A1 (es) |
| ZA (1) | ZA201604924B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201613864A (en) * | 2014-02-20 | 2016-04-16 | Takeda Pharmaceutical | Novel compounds |
| US10751378B2 (en) | 2014-04-17 | 2020-08-25 | Korea Research Institute Of Bioscience And Biotechnology | Pharmaceutical composition comprising Pistacia weinmannifolia extract, fraction of same or compound separated from same for preventing or treating chronic obstructive pulmonary disease (COPD) |
| CA3005918C (en) | 2015-11-23 | 2023-10-17 | Sunshine Lake Pharma Co., Ltd. | Octahydropyrrolo[3,4-c]pyrrole derivatives and uses thereof |
| KR102298546B1 (ko) * | 2018-10-18 | 2021-09-08 | 에이치케이이노엔 주식회사 | 신규한 n-(이소프로필-트리아졸릴)피리디닐)-헤테로아릴-카르복사미드 유도체 및 이의 용도 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4399256B2 (ja) * | 2001-06-28 | 2010-01-13 | スミスクライン ビーチャム ピー エル シー | オレキシン受容体アンタゴニストとしてのｎ−アロイル環状アミン誘導体 |
| WO2008038841A1 (fr) * | 2006-09-30 | 2008-04-03 | Japan Tobacco Inc. | Dérivé de thiadiazolone et utilisation de celui-ci |
| JP5847087B2 (ja) * | 2009-10-23 | 2016-01-20 | ヤンセン ファーマシューティカ エヌ．ベー． | オレキシン受容体調節因子としての縮合複素環式化合物 |
| US20110144081A1 (en) * | 2009-12-15 | 2011-06-16 | Henner Knust | Pyrrolidine derivatives |
| KR101689093B1 (ko) * | 2012-06-04 | 2016-12-22 | 액테리온 파마슈티칼 리미티드 | 벤즈이미다졸-프롤린 유도체 |
-
2015
- 2015-02-19 JP JP2016552540A patent/JP6466465B2/ja not_active Expired - Fee Related
- 2015-02-19 EP EP15706518.6A patent/EP3107907A1/en not_active Withdrawn
- 2015-02-19 AU AU2015220553A patent/AU2015220553B2/en not_active Expired - Fee Related
- 2015-02-19 CN CN201580009703.3A patent/CN106164064B/zh not_active Expired - Fee Related
- 2015-02-19 MA MA39229A patent/MA39229A1/fr unknown
- 2015-02-19 WO PCT/GB2015/050482 patent/WO2015124934A1/en active Application Filing
- 2015-02-19 EA EA201691673A patent/EA031982B1/ru not_active IP Right Cessation
- 2015-02-19 US US15/120,002 patent/US9790220B2/en not_active Expired - Fee Related
- 2015-02-19 CR CR20160373A patent/CR20160373A/es unknown
- 2015-02-19 MX MX2016010745A patent/MX2016010745A/es unknown
- 2015-02-19 KR KR1020167025660A patent/KR20160124188A/ko unknown
- 2015-02-19 SG SG11201606839SA patent/SG11201606839SA/en unknown
- 2015-02-19 CA CA2940047A patent/CA2940047A1/en not_active Abandoned
- 2015-02-19 GE GEAP201514272A patent/GEP20186909B/en unknown
- 2015-02-19 PE PE2016001444A patent/PE20161374A1/es unknown
-
2016
- 2016-07-15 ZA ZA2016/04924A patent/ZA201604924B/en unknown
- 2016-08-09 IL IL247195A patent/IL247195A0/en unknown
- 2016-08-15 PH PH12016501625A patent/PH12016501625A1/en unknown
- 2016-08-18 CL CL2016002085A patent/CL2016002085A1/es unknown
- 2016-09-15 EC ECIEPI201674482A patent/ECSP16074482A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA201691673A1 (ru) | 2017-01-30 |
| GEP20186909B (en) | 2018-10-25 |
| WO2015124934A1 (en) | 2015-08-27 |
| JP2017506239A (ja) | 2017-03-02 |
| WO2015124934A8 (en) | 2016-07-21 |
| PE20161374A1 (es) | 2016-12-17 |
| CN106164064A (zh) | 2016-11-23 |
| AU2015220553B2 (en) | 2019-06-27 |
| US9790220B2 (en) | 2017-10-17 |
| US20170073340A1 (en) | 2017-03-16 |
| EA031982B1 (ru) | 2019-03-29 |
| AU2015220553A1 (en) | 2016-07-21 |
| CR20160373A (es) | 2016-12-02 |
| CL2016002085A1 (es) | 2017-06-09 |
| CN106164064B (zh) | 2019-03-22 |
| IL247195A0 (en) | 2016-09-29 |
| ZA201604924B (en) | 2019-04-24 |
| ECSP16074482A (es) | 2018-05-31 |
| EP3107907A1 (en) | 2016-12-28 |
| KR20160124188A (ko) | 2016-10-26 |
| MX2016010745A (es) | 2017-02-02 |
| CA2940047A1 (en) | 2015-08-27 |
| MA39229A1 (fr) | 2018-01-31 |
| PH12016501625A1 (en) | 2016-11-07 |
| JP6466465B2 (ja) | 2019-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2512781B (en) | Network configuration | |
| GB201514875D0 (en) | Receptor | |
| HK1252163A1 (zh) | 受體 | |
| IL247854A0 (en) | Muscarinic receptor antagonists, preparations containing them and their uses | |
| SG11201610220QA (en) | Secured network bridge | |
| IL247194A0 (en) | Compounds of the cyclopentane type modified in positions 1 and 2 and their use as orexin type receptor antagonists | |
| GB2527276B (en) | Providing network credentials | |
| ZA201606141B (en) | Piperidine derivatives as orexin receptor antagonist | |
| IL247728B (en) | Piperdines -(3,5 di-converted-pyridine-4-yl)-1 | |
| HK1215115A1 (zh) | 無線網絡掃描策略 | |
| HRP20181585T1 (hr) | Selektivni nr2b antagonisti | |
| IL247195A0 (en) | Orexin receptor antagonists | |
| HK1247916A1 (zh) | 新型5-ht2拮抗劑 | |
| GB201404836D0 (en) | Novel Mat | |
| HK1191501A2 (en) | Mat | |
| ZA201807767B (en) | Angiotensin-1-receptor antagonists | |
| GB201707499D0 (en) | Orexin receptor antagonists | |
| GB201707504D0 (en) | Orexin receptor antagonists | |
| GB201702174D0 (en) | Orexin receptor antagonists | |
| PT3464324T (pt) | Antagonistas de recetores da angiotensina-1 | |
| AU201712378S (en) | Yoga mat | |
| GB201609075D0 (en) | Novel mat | |
| GB201508223D0 (en) | Novel mat |